Cargando…

The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity

Cyclophosphamide (CTX) is a major component of the chemotherapy conditioning regimens used in the clinic to prepare cancer patients for hematopoietic stem cell transplantation or adoptive T cell therapy. Previous studies have shown that CTX given at nonmyeloablative doses in mice and patients leads...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Zhi-Chun, Aboelella, Nada S., Bryan, Locke, Shi, Huidong, Zhou, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868404/
https://www.ncbi.nlm.nih.gov/pubmed/33569051
http://dx.doi.org/10.3389/fimmu.2020.594540
_version_ 1783648444536061952
author Ding, Zhi-Chun
Aboelella, Nada S.
Bryan, Locke
Shi, Huidong
Zhou, Gang
author_facet Ding, Zhi-Chun
Aboelella, Nada S.
Bryan, Locke
Shi, Huidong
Zhou, Gang
author_sort Ding, Zhi-Chun
collection PubMed
description Cyclophosphamide (CTX) is a major component of the chemotherapy conditioning regimens used in the clinic to prepare cancer patients for hematopoietic stem cell transplantation or adoptive T cell therapy. Previous studies have shown that CTX given at nonmyeloablative doses in mice and patients leads to expansion of myeloid cells within which the monocytic subset exhibits immunosuppressive activity. However, the ontogeny and gene expression signature of these CTX-induced monocytes are not well-defined. Here, we report that the expansion of myeloid cells is a default process intrinsic to hematopoietic recovery after chemotherapy. During this process, the monocytes repopulated in mice acquire immunosuppressive activity, which can persist long after cessation of chemotherapy. Moreover, monocytes acquire a gene signature characteristic of neutrophil precursors, marked by increased proliferative capability and elevated expressions of multiple primary and secondary granules. We provide evidence that CTX-induced myeloid cell expansion is regulated by DNA methyltransferase 1 (Dnmt1) and dependent on chemotherapy-induced microbial translocation. These findings help advance our understanding of the differentiation, heterogeneity, and function of myeloid cells repopulating after chemotherapy.
format Online
Article
Text
id pubmed-7868404
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78684042021-02-09 The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity Ding, Zhi-Chun Aboelella, Nada S. Bryan, Locke Shi, Huidong Zhou, Gang Front Immunol Immunology Cyclophosphamide (CTX) is a major component of the chemotherapy conditioning regimens used in the clinic to prepare cancer patients for hematopoietic stem cell transplantation or adoptive T cell therapy. Previous studies have shown that CTX given at nonmyeloablative doses in mice and patients leads to expansion of myeloid cells within which the monocytic subset exhibits immunosuppressive activity. However, the ontogeny and gene expression signature of these CTX-induced monocytes are not well-defined. Here, we report that the expansion of myeloid cells is a default process intrinsic to hematopoietic recovery after chemotherapy. During this process, the monocytes repopulated in mice acquire immunosuppressive activity, which can persist long after cessation of chemotherapy. Moreover, monocytes acquire a gene signature characteristic of neutrophil precursors, marked by increased proliferative capability and elevated expressions of multiple primary and secondary granules. We provide evidence that CTX-induced myeloid cell expansion is regulated by DNA methyltransferase 1 (Dnmt1) and dependent on chemotherapy-induced microbial translocation. These findings help advance our understanding of the differentiation, heterogeneity, and function of myeloid cells repopulating after chemotherapy. Frontiers Media S.A. 2021-01-25 /pmc/articles/PMC7868404/ /pubmed/33569051 http://dx.doi.org/10.3389/fimmu.2020.594540 Text en Copyright © 2021 Ding, Aboelella, Bryan, Shi and Zhou http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ding, Zhi-Chun
Aboelella, Nada S.
Bryan, Locke
Shi, Huidong
Zhou, Gang
The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title_full The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title_fullStr The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title_full_unstemmed The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title_short The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity
title_sort monocytes that repopulate in mice after cyclophosphamide treatment acquire a neutrophil precursor gene signature and immunosuppressive activity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868404/
https://www.ncbi.nlm.nih.gov/pubmed/33569051
http://dx.doi.org/10.3389/fimmu.2020.594540
work_keys_str_mv AT dingzhichun themonocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT aboelellanadas themonocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT bryanlocke themonocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT shihuidong themonocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT zhougang themonocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT dingzhichun monocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT aboelellanadas monocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT bryanlocke monocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT shihuidong monocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity
AT zhougang monocytesthatrepopulateinmiceaftercyclophosphamidetreatmentacquireaneutrophilprecursorgenesignatureandimmunosuppressiveactivity